ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00236964
Recruitment Status : Completed
First Posted : October 12, 2005
Last Update Posted : January 24, 2018
Sponsor:
Information provided by:
Luitpold Pharmaceuticals

Brief Summary:
The purpose of the study was to compare the efficacy of oral iron (ferrous sulfate) plus erythropoietin to Iron Sucrose plus erythropoietin for managing anemia patients with chronic renal failure who are not receiving dialysis.

Condition or disease Intervention/treatment Phase
Anemia Drug: Iron Sucrose + Erythropoietin Drug: Ferrous Sulfate + Erythropoietin Phase 3

Detailed Description:
Randomized open-label multicenter active-controlled study of anemic patients with Chronic Renal Failure who are not yet receiving dialysis. The duration of the study was five months. After screening procedures including multiple hemoglobin values, patients were randomly assigned to either IV Iron Sucrose (200mg X 5) or oral iron sulfate (325mg TID)for 29 days. Safety assessments included the recording of all adverse events, physical examinations, vital signs, electrocardiograms and clinical laboratory tests. Efficacy parameters included hematologic parameters.

Study Type : Interventional  (Clinical Trial)
Enrollment : 78 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis
Study Start Date : February 2001
Study Completion Date : May 2002

Resource links provided by the National Library of Medicine

U.S. FDA Resources




Primary Outcome Measures :
  1. Mean Change in Hemoglobin and Serum Ferritin at day 43

Secondary Outcome Measures :
  1. Clinical success (change in Hgb > 12 & Change in Ferritin 180)
  2. Maximum change in Hemoglobin during the study


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Creatine Clearance <40 mL/min
  • Average Baseline Hemoglobin < 10.5g/dL
  • TSAT < 25% and Ferritin <300ng/mL

Exclusion Criteria:

  • Blood Transfusion within 30days
  • Uncontrolled Hypertension
  • Suffering form concommitant disease of the liver
  • Serious bacterial infection
  • Pregnancy / lactation
  • Symptomatic HIV
  • Expected to under dialysis or renal transplant during study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00236964


Sponsors and Collaborators
Luitpold Pharmaceuticals
Investigators
Study Director: Mark Falone, MD Medical Director

Publications of Results:
ClinicalTrials.gov Identifier: NCT00236964     History of Changes
Other Study ID Numbers: 1VEN99012
First Posted: October 12, 2005    Key Record Dates
Last Update Posted: January 24, 2018
Last Verified: January 2018

Keywords provided by Luitpold Pharmaceuticals:
Anemia
Chronic Kidney Disease

Additional relevant MeSH terms:
Anemia
Renal Insufficiency
Kidney Failure, Chronic
Hematologic Diseases
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Iron
Ferric oxide, saccharated
Epoetin Alfa
Trace Elements
Micronutrients
Growth Substances
Physiological Effects of Drugs
Hematinics